Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145

PrintE-mail
Title Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145
Contact AWOLF
Principal Investigator Roberto Pili, MD
Study Number 213312
PhaseI/II
Summary To evaluate the safety profile, and to determine DLTs, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral TAK-733 in patients with advanced nonhematologic malignancies and melanoma.  To characterize the PK of TAK-733.
For more information about the clinical study go to Clinicaltrial.Gov